medroxalol medroxalol medroxalol is a vasodilator beta blocker also classified as a mixed receptor blocker as it blocks both alpha and beta receptors. medroxalolidentifiers iupac name 5-(2--1-hydroxyethyl)-2-hydroxybenzamide cas number56290-94-9pubchem cid41835chemspider38173unii7px96289jacomptox dashboard (epa)dtxsid30866550 echa infocard100.054.618 chemical and physical dataformulac20h24n2o5molar mass372.421 g·mol−13d model (jsmol)interactive image smiles o=c(n)c1cc(ccc1o)c(o)cnc(c)ccc2ccc3ococ3c2 inchi inchi=1s/c20h24n2o5/c1-12(2-3-13-4-7-18-19(8-13)27-11-26-18)22-10-17(24)14-5-6-16(23)15(9-14)20(21)25/h4-9,12,17,22-24h,2-3,10-11h2,1h3,(h2,21,25)key:mpqwsyjgfladew-uhfffaoysa-n synthesis medroxalol synthesis: for the first step, salicylamide (1) is the subject of a friedel-crafts acetylation and then the aromatic methylketone is halogenated. in the usual manner. the bromide in 2 is then displaced by the nitrogen in n-benzyl-1-(3',4'-methylenedioxyphenyl)-3-butylamine (3), which is itself prepared by reductive amination on the corresponding ketone. the product of the last step (4) is catalytically hydrogenated. this serves the dual purpose both of reducing the ketone and removing the benzyl protecting group affording the product medroxalol (5). note that a benzyl protecting group is not necessarily used.